Targeted
Medical Pharma, Inc. (OTCQB: TRGM) (the “Company”), a biotechnology
company that develops and distributes prescription medical foods to
physicians and pharmacies, today announced that its Form S-1
registration statement (the “Registration Statement”), which registers
up to 25,723,395 shares of common stock (“Shares”) for resale by selling
stockholders on a delayed or continuous basis, has cleared comments with
the United States Securities and Exchange Commission and accordingly,
the Company has requested the Registration Statement be declared
effective at 4:00 p.m. EST on April 19, 2013. The Company will not
receive any proceeds from the sale of the Shares by the selling
stockholders. All the proceeds from any sale of the Shares will be for
the respective account of each selling stockholder. The final prospectus
related to the Registration Statement can be accessed through EDGAR via www.sec.gov.
About Targeted Medical Pharma, Inc.
Targeted
Medical Pharma, Inc. is a Los Angeles-based biotechnology company
that develops prescription medical
foods for the treatment of chronic disease including pain syndromes,
peripheral neuropathy, hypertension, obesity, sleep and cognitive
disorders. The company manufactures ten proprietary prescription only
medical foods. These prescription medical foods and therapeutic systems
are sold to physicians and pharmacies in the U.S. through the company’s
subsidiary, Physician
Therapeutics. These proprietary medications represent a novel
approach to the management of certain disease states, focusing on safety
and efficacy without the deleterious side effects of traditional, high
dose prescription drugs. Targeted Medical Pharma also provides
diagnostic testing as well as billing and collection services on behalf
of dispensing physicians.
Forward Looking Statements
Certain statements contained herein constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may include, without limitation,
statements with respect to the Company’s plans and objectives,
projections, expectations and intentions. These forward-looking
statements are based on current expectations, estimates and projections
about the Company's industry, management's beliefs and certain
assumptions made by management. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance and
are subject to certain risks, uncertainties and assumptions that are
difficult to predict. Because such statements involve risks and
uncertainties, the actual results and performance of the Company may
differ materially from the results expressed or implied by such
forward-looking statements. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward-looking
statements. Unless otherwise required by law, the Company also disclaims
any obligation to update its view of any such risks or uncertainties or
to announce publicly the result of any revisions to the forward-looking
statements made here. Additional information concerning certain risks
and uncertainties that could cause actual results to differ materially
from that projected or suggested is contained in the Company’s filings
with the Securities and Exchange Commission (SEC), copies of which are
available from the SEC or may be obtained upon request from the Company.
